Navigation Links
Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
Date:10/26/2007

Live Webcasts from San Diego on November 2nd and New York on November 5th

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that the Company will present at three upcoming investor conferences:

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

-- Richard Ghalie, M.D., Chief Medical Officer, will present at the BIOCOM

Investor Conference at 11:00 a.m. Pacific time on Friday, November 2,

2007, from the San Diego Marriott Del Mar;

-- John P. Longenecker, Ph.D., President and Chief Executive Officer, will

present at the Acumen BioFin Rodman & Renshaw Healthcare Conference at

10:35 a.m. Eastern time on Monday, November 5, 2007, from the New York

Palace Hotel; and

-- Dr. Longenecker will also present at the CIBC World Markets Healthcare

Conference at 1:20 p.m. Eastern time on Monday, November 5, 2007, from

the Waldorf-Astoria in New York.

Live webcasts of all three presentations can be accessed at http://www.favrille.com. Replays will be available approximately one hour after each presentation and archived for one month.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the ... from its phase 1/2 tendon repair study investigating the use ... a treatment for Achilles tendinosis. ... The clinical trial met its ... and showed no serious adverse events related to the study ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished life sciences ... , Avomeen is a leader in a wide range of services related ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), a ... disease and more through a single-cell precision engineering platform, today announced it has ... in the laboratory of Dr. James Heath at the California Institute of ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small cell ... with limited tumor content in a large background of normal or wild type ... need for reliable detection of low abundance somatic mutations, particularly in small specimens ...
Breaking Biology Technology:
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
Breaking Biology News(10 mins):